- Tipo de expresión:
- Doctorado: Propuesta de dirección de tesis doctoral/temática para solicitar ayuda predoctoral ("Hosting Offer o EoI")
- Ámbito:
- Biomedicina
- Área:
- Vida
- Modalidad:
- Ayudas para contratos predoctorales para la formación de doctores (antiguas FPI)
- Referencia:
- 2023
- Centro o Instituto:
- CENTRO DE BIOLOGIA MOLECULAR SEVERO OCHOA
- Investigador:
- M.LUISA TORIBIO GARCIA
- Palabras clave:
-
- T-ALL leukemia, universal CAR-T cells, off-the-shelf immunotherapy, gene editing
PRE2023-OPTI-CAR-T-Superando los retos actuales de la inmunoterapia CAR-T frente a la leucemia LLA-T-PID2022-138880OB-I00
This predoctoral contract (former FPI program) is linked to the project “Overcoming current challenges of CAR‐T cell immunotherapy for T‐ALL leukemia with optimized CAR constructs (TRuCs) and universal, off‐the‐shelf, effector allogeneic T cells (OPTI‐CAR‐T)” (PID2022‐138880OB‐I00) funded by the Spanish Ministry of Science and Innovation (MICIN) and the State Research Agency (AEI). The widespread use of Chimeric Antigen Receptor- (CAR-) engineered T cells for immunotherapy is still in its infancy owing to important limitations The project is aimed at investigating and validating independent, but complementary, molecular and cellular innovative strategies focusing on optimisation of target recognition structures (chimeric antigen receptors, CARs) and effector T cells armed with them, which, in combination, are expected to overcome current challenges of CAR‐T immunotherapy for T‐cell acute lymphoblastic leukemia (T‐ALL). The general goal is to optimize the expression and function of endogenously regulated TCR‐fused CAR constructs (TRuCs) that target a surface molecule specifically expressed on T‐ALL cells, in combination with the production of universal, allogeneic effector CAR‐T cells (uCAR‐T) to express them, as the foundations of a next generation, off‐the‐shelf, universal CAR‐T immunotherapy for relapsed/refractory T-ALL validated in preclinic.